A Phase II, Open-Label Study of Ispinesib in Subjects With Platinum/Taxane-Refractory or Resistant Relapsed Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2008
At a glance
- Drugs Ispinesib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 09 Oct 2008 Checked against ClinicalTrials.gov record - last updated 9 Oct 2008.
- 19 Sep 2007 Status changed from in progress to completed.
- 05 Jan 2007 Status change